FLGT

Fulgent Genetics, Inc. NASDAQ

Healthcare ·Medical - Diagnostics & Research ·US · fulgentgenetics.com

$14.90

Mkt Cap $443.2M

52w Low $13.46 8.2% of range 52w High $31.04

50d MA $16.09 200d MA $22.17

P/E (TTM) -7.2x

EV/EBITDA -16.6x

P/B 0.4x

Debt/Equity 0.0x

ROE -5.4%

P/FCF -6.5x

RSI (14) —

ATR (14) —

Beta 0.89

50d MA $16.09

200d MA $22.17

Avg Volume 567.9K

About

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer … Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
May 1, 2026	BMO	-0.35	-0.36	-3.4%	15.19	-7.6%	-7.0%	-0.5%	-1.2%	—	—	—
Feb 27, 2026	BMO	0.03	0.16	+433.3%	24.76	-23.2%	-38.1%	-42.6%	-44.3%	-43.5%	-42.4%	—
Nov 7, 2025	BMO	-0.24	0.14	+158.3%	22.31	+7.8%	+18.2%	+21.7%	+27.2%	+30.3%	+32.6%	—
Aug 1, 2025	BMO	-0.23	0.07	+130.4%	17.18	+12.0%	+7.9%	+6.9%	+21.0%	+20.3%	+18.8%	—
May 2, 2025	BMO	-0.19	0.04	+121.1%	17.25	+5.5%	+19.1%	+13.4%	+9.1%	+8.1%	+7.6%	—
Feb 28, 2025	BMO	-0.31	0.04	+112.9%	15.69	+1.7%	-1.5%	-2.6%	-1.1%	+6.1%	+14.1%	—
Nov 8, 2024	BMO	-0.19	0.31	+263.2%	22.02	-0.8%	-11.8%	-9.0%	-13.0%	-16.3%	-19.2%	—
Aug 2, 2024	BMO	-0.31	0.15	+148.4%	23.57	-5.4%	+6.3%	+0.4%	+3.0%	-0.3%	+4.1%	—
May 3, 2024	BMO	-0.33	-0.01	+97.0%	21.24	-3.5%	+1.2%	+1.2%	+0.4%	+0.1%	+2.6%	—
Feb 28, 2024	BMO	-0.30	0.28	+193.3%	25.48	+0.0%	-8.1%	-11.5%	-8.8%	-6.8%	-8.9%	—
Nov 3, 2023	BMO	-0.33	-0.39	-18.2%	23.79	+2.4%	+13.2%	+14.0%	+11.4%	+11.1%	+9.7%	—
Aug 4, 2023	BMO	-0.33	-0.08	+75.8%	40.08	+9.8%	-3.0%	-15.4%	-16.8%	-18.1%	-18.9%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Nov 11	Piper Sandler	Maintains	Neutral → Neutral	—	$27.16	$27.47	+1.1%	+4.5%	+7.1%	+8.9%	+7.1%	+6.1%
Aug 5	UBS	Upgrade	Neutral → Buy	—	$18.36	$19.55	+6.5%	+13.2%	+12.6%	+11.2%	+10.9%	+12.3%
Aug 4	Piper Sandler	Maintains	Neutral → Neutral	—	$18.53	$18.56	+0.2%	-0.9%	+12.1%	+11.5%	+10.1%	+9.9%
May 6	Piper Sandler	Maintains	Neutral → Neutral	—	$19.56	$19.65	+0.5%	-3.8%	-4.7%	-5.1%	+0.7%	+2.9%
May 5	Raymond James	Maintains	Outperform → Outperform	—	$20.54	$19.86	-3.3%	-4.8%	-8.4%	-9.2%	-9.6%	-4.1%
Mar 4	Piper Sandler	Maintains	Neutral → Neutral	—	$15.28	$15.07	-1.4%	+1.6%	+9.0%	+17.1%	+21.7%	+10.5%
Nov 11	Piper Sandler	Maintains	Neutral → Neutral	—	$19.43	$19.84	+2.1%	+3.1%	-1.4%	-5.2%	-8.4%	-10.9%
Mar 6	Piper Sandler	Maintains	Neutral → Neutral	—	$23.22	$23.22	+0.0%	+0.6%	+1.8%	-1.3%	+0.2%	-2.0%
Oct 16	Piper Sandler	Maintains	Neutral → Neutral	—	$24.90	$24.89	-0.0%	+0.9%	+0.6%	+1.2%	+2.2%	+2.0%
Mar 2	Credit Suisse	Maintains	Outperform → Outperform	—	$31.85	$31.39	-1.4%	+4.9%	+5.9%	-2.0%	-2.2%	-1.4%
Dec 8	Piper Sandler	Downgrade	Overweight → Neutral	—	$37.07	$35.67	-3.8%	-9.1%	-8.1%	-10.0%	-9.1%	-9.1%
Nov 18	Raymond James	Maintains	Outperform → Outperform	—	$35.89	$37.24	+3.8%	+3.2%	+2.3%	+0.3%	+1.7%	+2.8%
Nov 14	Credit Suisse	Maintains	Outperform → Outperform	—	$39.24	$38.73	-1.3%	-8.5%	-5.7%	-8.4%	-8.5%	-5.6%
Nov 14	Piper Sandler	Maintains	Overweight → Overweight	—	$39.24	$38.73	-1.3%	-8.5%	-5.7%	-8.4%	-8.5%	-5.6%
Aug 25	Credit Suisse	Maintains	Outperform → Outperform	—	$46.96	$47.77	+1.7%	+2.4%	-1.2%	-4.6%	-6.0%	-7.4%
May 16	Piper Sandler	Maintains	Overweight → Overweight	—	$54.45	$54.31	-0.3%	-1.5%	+4.2%	+1.9%	+5.8%	+3.0%
Jan 25	Oppenheimer	Maintains	Outperform → Outperform	—	$60.72	$60.10	-1.0%	+4.6%	+2.1%	-0.4%	+3.2%	+5.2%
Aug 10	Credit Suisse	Maintains	Underperform → Underperform	—	$109.76	$95.00	-13.4%	-11.3%	-13.3%	-9.7%	-14.2%	-12.5%
Mar 5	Piper Sandler	Maintains	Overweight → Overweight	—	$85.53	$110.88	+29.6%	+8.0%	+10.6%	+28.1%	+13.6%	+19.6%
Feb 1	Oppenheimer	Maintains	Outperform → Outperform	—	$110.49	$112.30	+1.6%	+24.8%	+2.1%	+14.6%	+7.9%	+28.1%
Jan 8	Credit Suisse	Downgrade	Neutral → Underperform	—	$70.84	$71.00	+0.2%	-10.6%	-12.4%	-1.3%	-1.4%	-2.5%
Nov 24	BTIG	Downgrade	Buy → Neutral	—	$43.60	$42.35	-2.9%	-15.3%	-16.3%	-6.8%	+3.0%	+5.2%
Sep 25	Credit Suisse	Maintains	Neutral → Neutral	—	$39.52	$39.53	+0.0%	-0.4%	-1.5%	+5.8%	+1.3%	+2.8%
Aug 20	Oppenheimer	Maintains	Outperform → Outperform	—	$44.01	$45.38	+3.1%	+14.8%	+9.1%	+3.7%	+4.4%	+1.8%
Jul 27	Piper Sandler	Maintains	Overweight → Overweight	—	$19.51	$19.92	+2.1%	+35.6%	+31.6%	+31.5%	+33.9%	+35.1%
Jun 17	Piper Sandler	Maintains	Overweight → Overweight	—	$16.50	$19.30	+17.0%	-1.0%	+1.3%	+1.8%	+4.2%	+6.1%
May 29	BTIG	Maintains	Buy → Buy	—	$16.06	$16.70	+4.0%	+8.5%	+12.1%	+13.8%	+9.6%	+5.2%
May 5	Credit Suisse	Maintains	Neutral → Neutral	—	$16.48	$16.91	+2.6%	-23.5%	-11.6%	-4.9%	+0.6%	+1.7%
Nov 5	Piper Jaffray	Upgrade	Neutral → Overweight	—	$9.40	$11.50	+22.3%	+38.4%	+26.9%	+31.1%	+68.3%	+58.0%
Nov 5	Piper Sandler	Upgrade	Neutral → Overweight	—	$9.40	$11.50	+22.3%	+38.4%	+26.9%	+31.1%	+68.3%	+58.0%
Apr 26	Credit Suisse	Downgrade	Outperform → Neutral	—	$7.35	$7.25	-1.4%	-6.8%	-10.3%	-9.5%	-6.8%	-6.1%
May 9	Credit Suisse	Maintains	Outperform → Outperform	—	$3.88	$3.80	-2.0%	-2.3%	-4.6%	-2.1%	-4.4%	-4.4%
Mar 1	Piper Sandler	Downgrade	Overweight → Neutral	—	$4.79	$4.58	-4.4%	-10.0%	-20.3%	-21.7%	-20.7%	-20.5%
Mar 1	Credit Suisse	Maintains	Outperform → Outperform	—	$4.79	$4.58	-4.4%	-10.0%	-20.3%	-21.7%	-20.7%	-20.5%
Mar 1	PiperJaffray	Downgrade	Overweight → Neutral	—	$4.79	$4.58	-4.4%	-10.0%	-20.3%	-21.7%	-20.7%	-20.5%
Nov 7	Credit Suisse	Maintains	Outperform → Outperform	—	$4.05	$3.33	-17.8%	-14.3%	-15.3%	-17.2%	-18.0%	-19.5%
Aug 8	Credit Suisse	Maintains	Outperform → Outperform	—	$6.14	$5.76	-6.2%	-12.2%	-8.1%	-5.9%	-6.2%	-3.6%
Oct 24	Credit Suisse	Maintains	Outperform → Outperform	—	$8.88	$8.85	-0.3%	+2.6%	+4.7%	+1.6%	+1.2%	+2.4%
Oct 24	BTIG Research	Maintains	Buy → Buy	—	$8.88	$8.85	-0.3%	+2.6%	+4.7%	+1.6%	+1.2%	+2.4%

Recent Filings

8-K · 5.02 !!! Very High

Unknown — 8-K 5.02: Executive Change

I need more details about the executive change to provide meaningful analysis. Could you clarify: 1. Which company (CNVS or FLGT)? 2. What position changed? 3. Is this a departure, hire, or promotion? 4. Who is involved? Without these specifics, I cannot write an accurate assessment of stock implications.

Apr 15

8-K · 7.01 ! Medium

Unknown — 8-K 7.01: Regulation FD Disclosure

OraSure's stabilizing public health funding and near-term catalysts position it for revenue growth and margin expansion, making OSUR attractive for investors seeking profitability turnaround potential.

Mar 30

8-K · 2.01 !!! Very High

Unknown — 8-K 2.01: Acquisition Completed

FLGT completed a $43M acquisition, which could accelerate growth and market expansion, though investors should monitor integration costs and whether synergies justify the purchase price.

Mar 17

8-K · 7.01 ! Medium

Fulgent Genetics, Inc. -- 8-K 7.01: Regulation FD Disclosure

Fulgent Genetics updated its investor presentation on February 27, 2026, providing current business summaries and updates available on its investor relations website.

Feb 27

Data updated apr 25, 2026 9:20am · Source: massive.com